GENETIC ANALYSIS NK -60 Cash Flow-to-Debt Ratio
GENETIC ANALYSIS NK -60 cash flow-to-debt ratio. GENETIC ANALYSIS NK -60 (8V8) has a Cash Flow-to-Debt Ratio of -0.19x as of June 2026, meaning its operating cash flow of €-4.52 Million could theoretically repay 0% of its total liabilities (€23.93 Million) in one year. See 8V8 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GENETIC ANALYSIS NK -60 (2021–2025)
Cash flow-to-debt ratio of GENETIC ANALYSIS NK -60 from 2021 to 2025. Historical debt coverage capacity for GENETIC ANALYSIS NK -60 across 5 annual periods. Check GENETIC ANALYSIS NK -60 investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
GENETIC ANALYSIS NK -60 Cash Flow-to-Debt Ratio by Year (2021–2025)
GENETIC ANALYSIS NK -60 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for GENETIC ANALYSIS NK -60. For the full cash flow conversion analysis, see 8V8 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | €2.40 Million | €25.37 Million | ▲ +116.2% |
| 2024 | -0.58x | €-11.62 Million | €19.88 Million | ▲ +27.1% |
| 2023 | -0.80x | €-17.23 Million | €21.49 Million | ▲ +16.4% |
| 2022 | -0.96x | €-19.46 Million | €20.28 Million | ▲ +60.4% |
| 2021 | -2.42x | €-27.62 Million | €11.40 Million | — |